Merit Medical (MMSI) Systems announced that the WRAPSODY Cell-Impermeable Endoprosthesis has received premarket approval from the US Food and Drug Administration. With this approval, Merit can begin commercialization of the device in the USA in 2025. WRAPSODY is designed to extend long-term vessel patency in dialysis patients. Many patients undergoing dialysis rely on a vascular access site created in the arm called an arteriovenous fistula or an AV graft. The maintenance of adequate blood flow through these sites is crucial for patient survival. Over time, life-threatening access site complications can arise, including stenosis and thrombosis.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical Systems Announces Leadership Change Amid Investigation
- Merit Medical announces resignation of president Joseph Wright
- Reddit initiated, GE Vernova downgraded: Wall Street’s top analyst calls
- Merit Medical upgraded to Overweight from Equal Weight at Wells Fargo
- Merit Medical price target raised to $127 from $125 at Canaccord